- Cassava Sciences (SAVA) secures a new U.S. patent covering lead candidate sumifilam (PTI-125). The claims pertain to inhibiting a TLR4-mediated immune response via one or more unique filamin A-binding molecules.
- Its patent estate, now totaling seven, in the area of filamin-binding molecules runs through 2037.
- The company says sumifilam restores the normal shape of filamin A in the brain, improving the function of multiple brain receptors and dampening neuroinflammation in Alzheimer’s patients.
- Previously: Cassava Sciences rallies on hopes for Alzheimer's candiate PTI-125 (June 3)